DiaMedica Therapeutics Inc (NASDAQ:DMAC) price on Thursday, July 03, rose 5.32% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $3.76.
A look at the stock’s price movement, the close in the last trading session was $3.57, moving within a range at $3.55 and $3.81. The beta value (5-Year monthly) was 1.201. Turning to its 52-week performance, $6.82 and $2.80 were the 52-week high and 52-week low respectively. Overall, DMAC moved -8.74% over the past month.
DiaMedica Therapeutics Inc’s market cap currently stands at around $161.24 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-13.
Turning to the stock’s technical picture we see that short term indicators suggest on average that DMAC is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend DMAC as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
DMAC’s current price about -1.44% and -5.42% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 47.18, while 7-day volatility ratio is 8.23% and 7.81% in the 30-day chart. Further, DiaMedica Therapeutics Inc (DMAC) has a beta value of 1.24. Analysts have given the company’s stock an average 52-week price target of $8, forecast between a low of $7 and high of $10. Looking at the price targets, the low is -86.17% off current price level while to achieve the yearly target high, price needs to move -165.96%. Nonetheless, investors will most likely welcome a -112.77% jump to $8 which is the analysts’ median price.
If we refocus on DiaMedica Therapeutics Inc (NASDAQ:DMAC), historical trading data shows that trading volumes averaged 0.51 over the past 10 days and 165.03K over the past 3 months. The company’s latest data on shares outstanding shows there are 42.86 million shares.
The 43.69% of DiaMedica Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 17.86% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.23 million on 2025-06-13, giving us a short ratio of 10.88. The data shows that as of 2025-06-13 short interest in DiaMedica Therapeutics Inc (DMAC) stood at 456.00000000000006 of shares outstanding, with shares short rising to 0.86 million registered in 2025-05-15. Current price change has pushed the stock 27.46% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the DMAC stock continues to rise going into the next quarter.
